Iambic Therapeutics, Inc. (IAM)
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Iambic Therapeutics Inc.
NASDAQ:IAMTechnology · Software - Application
-2.79%$14.26
AH Close$14.34+0.56%vs close
AH Close$14.34+0.56%vs close
Mkt Cap$675.94M
Float34.5M
O/S47.4M
Inst Own-
Dilution